Zydus Cadila division settles patent litigation with Adamas Pharma over dyskinesia drug Gocovri

An announcement in this regard was recently made by Adamas Pharma.

Under the settlement agreement, Adamas grants Zydus a non-exclusive license to make, use, sell, offer to sell, and import generic versions of GOCOVRI as of March 4, 2030, or earlier in certain circumstances, including the potential for an accelerated license date if the unit sales of GOCOVRI in the 12-month period ending July 31, 2025, or any subsequent 12-month period decline by a specified percentage below the unit sales of GOCOVRI in the year ended December 31, 2019.

GOCOVRI (amantadine) extended-release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also the only medicine clinically proven to reduce both dyskinesia and OFF.

"I am pleased to announce the swift settlement of this litigation which reaffirms the strength of our intellectual property and gives us confidence in the opportunity to deliver GOCOVRI to the patients who may benefit for years to come," said Neil F. McFarlane, Chief Executive Officer.

"We are focused on building on the momentum from our strong 2020 performance and delivering growth for GOCOVRI in 2021, " he added.

In accordance with the settlement agreement, the parties will submit a joint stipulation and order to the United States District Court for the District of New Jersey, and the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice. Upon entry of the joint stipulation and order, this settlement agreement will conclude all patent litigation brought to date by Adamas against generic pharmaceutical companies that filed an ANDA seeking approval to market generic versions of GOCOVRI prior to the expiration of the patents listed in the Orange Book.